Israeli Stocks: Leumi, Teva, BioLineRx, EZchip, Allot, Redhill
Israel’s TA-25 index advanced 0.4 percent to 1,121 at the 5 p.m. close in Tel Aviv. The close was delayed after the bourse opened an hour late as a general strike that shut the exchange for two days ended. Investors traded about 720 million shekels ($193 million) of shares and convertible securities, according to bourse data.
The following stocks rose or fell today. Symbols are in parentheses.
Allot Communications Ltd. (ALLT) (ALLT IT) tumbled 9.4 percent, the most since Oct. 2, to 61.19 shekels or the equivalent of $16.44. The Israeli maker of high-speed networking equipment’s U.S.-traded shares closed at $16.13 in New York on Feb. 10.
BioLineRX Ltd. (BLRX) retreated 8.3 percent to 1.522 shekels or the equivalent of 41 cents, the lowest close since Jan. 31. The biopharmaceutical company’s ADRs, each representing 10 shares, closed at $3.93 in New York last week.
EZchip Semiconductor Ltd. (EZCH) soared to the highest on record, jumping 12 percent to 138.50 shekels, or $37.22. The U.S-traded shares of the processor maker closed at $37.06.
Bank Leumi Le-Israel Ltd. (LUMI) advanced 2.8 percent, the most since Jan. 26, to 12.28 shekels. The board of the country’s largest lender by assets approved measures that will cut costs by as much as 400 million shekels a year.
Perrigo Co. (PRGO) lost 4.4 percent, the most since Oct. 30, to 349.80 shekels, or the equivalent of $94. The New York- traded shares of the largest U.S. maker of generic over-the- counter drugs, closed at $93.31.
Redhill Biopharma Ltd. (RDHL) (RDHL IT) advanced 2.8 percent, the most since Jan. 19, to 2.201 shekels. The biopharmaceutical company received U.S. Food and Drug Administration approval for a clinical trial of its RHB-102 drug against nausea and vomiting in cancer treatments.
Teva Pharmaceutical Industries Ltd. (TEVA) declined to the lowest since Jan. 3, retreating 1.7 percent to 165.60 shekels, or $44.50. The U.S.-traded shares of the world’s biggest maker of generic drugs closed at $44.16.
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org
Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.